Your fact-checks will appear here
Ivermectin as a therapy for liver fibrosis or nonalcoholic fatty liver disease (NAFLD)
The human body clears ivermectin mainly through metabolism and fecal excretion, with a plasma half-life of roughly 18 hours and metabolites that can persist longer — some reported at ~55 hours — so el...
Ivermectin’s pharmacokinetics are shaped by its high lipophilicity, producing clear differences between low‑body‑weight (including undernourished children) and obese subjects: obese individuals tend t...
No completed or registered human clinical trials testing ivermectin specifically as a therapy for liver fibrosis or nonalcoholic fatty liver disease (NAFLD) are identified in the provided reporting; t...